Geron Corporation is a biotechnology company focused on developing innovative therapies for cancer treatment, particularly through its lead product candidate, which targets hematologic malignancies. The company is dedicated to advancing its proprietary telomerase technology to create effective and safe treatment options for patients with various types of cancer. By leveraging its scientific expertise and clinical research capabilities, Geron aims to address unmet medical needs and improve patient outcomes in the oncology field. Read More
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.
Dur
Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS.
Chief Executive Officer Harout Semerjian said first-half net
Geron's Q3 2025 results show mixed performance, with RYTELO revenue up 67% year-over-year but missing analyst sales estimates, causing a negative market reaction.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences:
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF).
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 26,500 shares of common stock, to three newly hired employees and (ii) October 20, 2025, covering an aggregate of 1,500,000 shares of its common stock to one newly hired employee, each as an inducement material to their acceptance of employment with Geron.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on September 4, 2025 at the 2025 Wells Fargo Healthcare Conference in Boston, MA.
